Cinclus Pharma Holding AB
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cinclus Pharma Holding AB - overview
Established
2014
Location
Stockholm, -, Sweden
Primary Industry
Biotechnology
About
Cinclus Pharma Holding AB is dedicated to developing innovative therapeutic solutions for gastric acid-related diseases, focusing on gastroesophageal reflux disease (GERD) and H. pylori infections, particularly through its key product candidate linaprazan glurate. Cinclus Pharma, founded in 2014, is based in Stockholm, Sweden. The company specializes in creating therapeutic solutions for gastric acid-related conditions, particularly GERD.
Marek Poszepczynski is the founder, who has a history of involvement in healthcare ventures. The firm raised SEK 240. 000 mn in its latest funding round on May 20, 2022, led by Trill Impact and including investors like Eir Ventures and Fjärde AP-Fonden. This funding represents the total amount raised by the company.
Cinclus Pharma focuses on developing linaprazan glurate, a Potassium-Competitive Acid Blocker (P-CAB) aimed at improving the management of GERD symptoms. The product has completed multiple Phase I trials and a Phase II trial in 2022. The company's primary market for commercialization is in Europe, facilitated through partnerships with other pharmaceutical firms such as Zentiva for distribution. In 2023, Cinclus Pharma reported a revenue of SEK 561,955.
70 with an EBITDA of SEK -18,834,804. 60. The company generates revenue through partnerships and licensing agreements, enabling the commercialization and manufacturing of linaprazan glurate, primarily through a B2B model with strategic pharmaceutical partners. Cinclus Pharma plans to utilize the SEK 240.
000 mn raised in May 2022 to enhance its financial position and advance its commercialization strategy. The company aims to expand its market presence in Europe and potentially explore new geographic regions to distribute linaprazan glurate. There are no specific upcoming product launches mentioned, but the funding will support ongoing initiatives to strengthen its market strategy. In March 2026, Cinclus Pharma Holding AB raised EUR 28 million in venture debt funding from new investor Claret Capital Partners.
The company plans the March 2026 funding to support its Phase III clinical development and pre‑launch activities.
Current Investors
AP-Fonden 4, Recipharm Venture Fund, Fjärde AP-Fonden
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Pharmaceuticals
Website
www.cincluspharma.com
Verticals
HealthTech, Manufacturing
Total Amount Raised
Subscriber access only
Cinclus Pharma Holding AB - timeline of key events
Cinclus Pharma Holding AB - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - |
| EBITDA (USD) | (246,101) | (524,965) | (909,000) | (84,202,000) | - | - | - |
| Operating Income (USD) | (246,101) | (524,965) | (909,000) | (84,285,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - |
| NET Income (USD) | (231,852) | (1,270,012) | (2,051,000) | (76,266,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - |
Cinclus Pharma Holding AB - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.